Related Experiment Video
Updated: Aug 23, 2025
06:08
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
344
[Experiences with MRI-guided brachytherapy for radiorecurrent prostate cancer]
Marnix J A Rasing1, Max Peters1,2, M A Moerland1
1UMC Utrecht, Cancer Center, afd. Radiotherapie, Utrecht.
Nederlands Tijdschrift Voor Geneeskunde
|October 27, 2022
Summary
MR-guided brachytherapy provides focal salvage treatment for recurrent prostate cancer, minimizing toxicity to surrounding organs. This approach offers a chance for cure and can delay androgen deprivation therapy in select patients.
Area of Science:
- Oncology
- Radiation Oncology
- Urologic Oncology
Context:
- Prostate cancer recurrence after radiotherapy requires effective salvage options.
- Minimizing toxicity to the bladder, urethra, and rectum is crucial in salvage treatment.
- Focal treatment of isolated local recurrence is an emerging strategy.
Purpose:
- To evaluate MR-guided brachytherapy as a focal salvage treatment for local recurrence of prostate cancer.
- To assess the efficacy and toxicity profile of MR-guided brachytherapy in this setting.
- To identify patient selection criteria for optimal outcomes with MR-guided brachytherapy.
Summary:
- MR-guided brachytherapy targets localized prostate cancer recurrence post-radiotherapy.
- This focal approach aims to reduce side effects on adjacent organs like the bladder, urethra, and rectum.
- Initial treatment response is common, with durable results in approximately half of patients.
- Patient factors including symptoms, recurrence characteristics, and PSA kinetics influence suitability for treatment.
Impact:
- Offers a potential cure for select patients with recurrent prostate cancer.
- Defers the need for androgen deprivation therapy, preserving quality of life.
- Provides a minimally invasive salvage option with reduced toxicity compared to whole-gland treatments.
